Health outcomes in type 2 diabetes with sudden kidney problems: combined SGLT2 inhibitor and GLP-1 receptor agonist treatment compared to single treatments

Among 29,269 patients, 1,591 (5.4%) received combined therapy of SGLT2 inhibitors and GLP-1 receptor agonists.

• The combined therapy group had significantly lower risks of all-cause mortality compared to SGLT2 inhibitor monotherapy (adjusted hazard ratio = 0.53) and GLP-1 receptor agonist monotherapy (adjusted hazard ratio = 0.43) after a mean follow-up of 2.4 years.
• Lower risks of major adverse kidney events were observed in the combined therapy group compared to SGLT2 inhibitor monotherapy (adjusted hazard ratio = 0.70) and GLP-1 receptor agonist monotherapy (adjusted hazard ratio = 0.45) after a mean follow-up of 2.7 years.
• The risk of major adverse cardiovascular events was similar across all treatment groups.
• The combined therapy group had a higher risk of hypoglycemia (adjusted hazard ratio = 1.51) and diabetic retinopathy (adjusted hazard ratio = 1.59) compared to the SGLT2 inhibitor monotherapy group.

Simplified